Supernus Pharma SEC Filings

Supernus Pharmaceuticals (SUPN) furnished an 8-K announcing Q3 2025 results and a supply update for ONAPGO. The company furnished a press release with financial results for the quarter ended September 30, 2025, and hosted a live webcast at 4:30 p.m. Eastern Time on November 4. The webcast will be archived on the company’s website for 60 days.

Supernus also disclosed a temporary supply constraint for ONAPGO driven by stronger than expected demand. To manage the imbalance, the company is prioritizing care for patients currently on therapy and pausing delivery to patients who have not yet started ONAPGO. Supernus is working to build inventory and aims to resume new patient initiations as soon as possible, with updates to follow.

Supernus Pharmaceuticals (SUPN) announced it will report third quarter 2025 results after the market closes on November 4, 2025.

Management will host a conference call and webcast on November 4, 2025 at 4:30 p.m. ET to discuss its financial and business results.

The announcement was furnished via a press release included as Exhibit 99.1.

Supernus Pharmaceuticals filed an amended current report to add required financial statements and pro forma information related to its acquisition of Sage Therapeutics. The deal followed a tender offer at $8.50 per share in cash plus one CVR per share, which can pay up to $3.50 per share if specified milestones are achieved by June 30, 2026; December 31, 2027; December 31, 2028; and December 31, 2030. The offer expired on July 30, 2025, was accepted and paid, and Sage merged into a Supernus subsidiary on July 31, 2025 under Section 251(h), becoming a wholly owned subsidiary.

The amendment supplies Sage’s audited 2023–2024 financials, unaudited interim financials for the three and six months ended June 30, 2024 and 2025, and unaudited pro forma condensed combined statements, including a balance sheet as of June 30, 2025 and statements of operations for the six months ended June 30, 2025 and the year ended December 31, 2024, plus a PwC consent. The pro formas are presented for informational purposes only.

Insider transactions by the CEO/President and director Jack A. Khattar are reported on this Form 4. On 10/09/2025 Mr. Khattar exercised 81,250 employee stock options with an exercise price of $25.30 and immediately sold a total of 59,900 common shares in multiple transactions at weighted average prices of $50.55 and $51.46. After these transactions he directly beneficially owns 1,206,578 shares and indirectly holds 1,005,600 shares through the KBT Trust. The option grant vests in four equal installments that began on 02/24/2018.

Insider sale under 10b5-1 plan: A company director, Charles W. Newhall III, reported sales of a total of 25,000 shares of Supernus Pharmaceuticals, Inc. (SUPN) executed on 10/09/2025 under a trading plan adopted 03/03/2025. The sales are recorded as two blocks: 23,800 shares at a weighted average price of $50.73 and 1,200 shares at a weighted average price of $51.55, leaving beneficial ownership reported at 104,644 shares after the transactions.

The reporter certified the transactions were made pursuant to a Rule 10b5-1 plan and provided weighted-price ranges: $50.12–$51.08 for the larger block and $51.39–$51.76 for the smaller block. The Form 4 was signed by an attorney-in-fact on 10/10/2025.

Supernus Pharmaceuticals (SUPN) notice reports a proposed sale of 59,900 common shares, with an aggregate market value of $2,875,200, to be sold on or about 10/09/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The shares were acquired the same day by exercise of stock options and paid in cash. The filer also disclosed multiple prior 10b5-1 plan sales across August–October 2025 totaling substantial proceeds (individual trades range from $45,001 to $2,558,888.12), showing ongoing systematic insider selling. The filer affirms no undisclosed material nonpublic information and provides standard Rule 144 representations.

Notice of proposed sale under Rule 144 for Supernus Pharmaceuticals, Inc. (SUPN) reports an intended sale of 25,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $1,200,000.00. The shares were acquired on 05/01/2012 as an in-kind distribution from NEA Partners. The filing lists total shares outstanding as 56,073,088, and an approximate sale date of 10/09/2025 on the NASDAQ. The filer also disclosed recent Rule 10b5-1 executed sales by Charles Newhall totaling 6,000 shares across three trades on 08/22/2025, 08/25/2025, and 08/27/2025

Supernus Pharmaceuticals (SUPN) reported insider equity activity by its President, CEO and Director on 10/02/2025. The reporting person acquired 20,000 and 19,320 shares of common stock at $0 upon settlement of performance share units granted in 2021 and 2024. To cover taxes, the company withheld 7,796 and 7,529 shares at $46.21.

Following these transactions, the reporting person directly beneficially owned 1,185,228 shares. An additional 1,005,600 shares were beneficially owned indirectly via the KBT Trust. The performance share unit awards vested based on achievement of individual performance objectives set in 2021 and 2024.

Supernus Pharmaceuticals insider activity shows the company's President and CEO, Jack A. Khattar, completed option exercise and open-market sale transactions on 10/02/2025. He exercised 2,267 employee stock options at an exercise price of $25.3 per share, resulting in direct ownership of those 2,267 shares. On the same date he sold 1,904 shares in multiple trades at a weighted average price of $48.06. After these transactions the reporting person directly beneficially owned 1,161,233 shares and indirectly held 1,005,600 shares through the KBT Trust.

The exercise was made under an employee option schedule that vests in installments beginning 02/24/2018, and the sale was executed pursuant to a 10b5-1 trading plan adopted 11/14/2024. The filer offers to provide detailed breakdowns of sale prices within the reported $48.00–$48.08 range on request.